<DOC>
	<DOC>NCT01986335</DOC>
	<brief_summary>The objectives of this study were to analyze the immunogenicity and reactogenicity of DTP/HB/Hib (Bio Farma) combination vaccine.</brief_summary>
	<brief_title>Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial</brief_title>
	<detailed_description>This trial was randomized, double blind, prospective intervention and multi centers. Total 600 subject (6-11 weeks of ages) followed this trial, divided into 3 groups, each group consists of 200 subjects. A number of 342 subjects were recruited in Bandung, while 258 subjects were recruited in Jakarta.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Infant 611 week of age Infant born after 3742 week of pregnancy Infant weighting more than 2.5 kg at birth Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form Parents commit themselves to comply with the indication of the investigator and with the schedule of the trial Mother at least graduate from elementary school Received Hepatitis B vaccine (Bio Farma) at birth Child concomitantly enroll or schedule to be enroll in another trial Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature &gt;=37.5 Celsius on Day 0) Known history of allergy to any component of the vaccine component (e.g.formaldehyde) History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular injection Known history of congenital or acquired immunodeficiency (including HIV infection) Child who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulin, blood derived product or long term corticotherapy (&gt;2 weeks) Other vaccination within the 1 month prior to inclusion with the exception of BCG and poliomyelitis Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objective Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>11 Weeks</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Combined pentavalent DTP/HB/Hib vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>Primary vaccination</keyword>
</DOC>